🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchEcnoglutide, mazdutide, and other emerging GLP-1 pipeline agents Page 3

Ecnoglutide, mazdutide, and other emerging GLP-1 pipeline agents

TrialTracker_MD Thu, Jun 4, 2026 at 9:47 AM 19 replies 418 viewsPage 3 of 4
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
Jun 5, 2026 at 3:12 AM#11
Dr.MetabolicMD said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Bookmarking. The distinction being drawn above is the one nobody else makes.

Last edited: Jun 5, 2026 at 5:12 AM
32 7Dr.EndoEP, GraceAZ_72, carl_compliance and 29 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Jun 5, 2026 at 9:45 AM#12

From the other side of the consultation, briefly. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

Last edited: Jun 5, 2026 at 11:45 AM
31 6NauseaFreeNow, SteveThurs, B12Beth and 28 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Jun 5, 2026 at 4:18 PM#13
Dr.DermMIA said:
If two explanations both fit, the useful question is which one predicts something the other does not.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.

30 5PharmHunterJen, TomTeleRx, DoseLogDan and 27 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Jun 5, 2026 at 10:51 PM#14

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

29 4sophie_paris, mel_PDX, Dr.AddMedPHL and 26 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 6, 2026 at 5:24 AM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Tagging this one for the weekly digest.

28 3PurityPaulOR, MaxMetOK, MounjBrad and 25 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register